Top Markets
Coin of the day
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
Clasificación en acciones #25837
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Precio por acción
$0.74834668
Capitalización bursátil
$45.86M
Cambio (1 día)
-0.15%
Cambio (1 año)
-6.28%
País
SE
Comercio Mendus AB (publ) (IMMU)

Categoría

Historial de desdoblamientos de acciones de Mendus AB (publ) (IMMU)
La acción Mendus AB (publ) (símbolo: IMMU) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 20, 2026.
Una acción IMMU comprada antes de Aug 20, 2026 equivaldría hoy a 0 acciones IMMU.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
NL
1 x3
AU
0 -
CH
0 -
US